AngioJet药物机械取栓联合导管溶栓与单纯导管溶栓治疗髂股深静脉血栓的对比:单中心回顾性队列研究
该单中心回顾性队列研究纳入2011至2017年因症状性急性髂股深静脉血栓接受溶栓治疗的151条患肢,比较AngioJet药物机械取栓联合导管溶栓(PCDT,70条)与单纯导管溶栓(CDT,81条)的结局。结果显示两组血栓后综合征发生率无显著差异,PCDT组溶栓时间及溶栓剂量显著降低,出血有减少趋势但未达统计学意义,血红蛋白尿增加而急性肾损伤无显著差异,两年血管通畅率无显著差异。
要点
- PCDT与单纯CDT的血栓后综合征发生率无显著差异(22.2% vs 24.7%,p=.74)。
- PCDT显著缩短溶栓时间并减少溶栓剂量,出血有减少趋势但未达统计学意义。
- PCDT增加血红蛋白尿但未增加急性肾损伤,两年血管通畅率无显著差异。
核心结论
- 对于髂股深静脉血栓,PCDT提供了与单纯CDT相当的患者结局和血管通畅率、可接受的安全性,并减少总体溶栓剂量。
研究设计与样本
- 单中心回顾性队列研究,回顾2011至2017年因症状性急性髂股深静脉血栓接受溶栓治疗的患者,共治疗151条患肢,其中PCDT组70条、单纯CDT组81条。
- 所有患者随访至少一年。
主要发现
- 一年时Villalta评分诊断的血栓后综合征发生率两组无显著差异(22.2% PCDT vs. 24.7% CDT alone,p = .74)。
- PCDT组出血有减少趋势但未达统计学意义(4/63 [6.3%] vs. 13/76 [17.1%];相对风险0.37,95%CI 0.13-1.08;p = .07)。
- PCDT组溶栓持续时间显著缩短(40 h [95%CI 34-46] vs. 53 h [95%CI 49-58];p < .001),溶栓剂量显著减少(49 mg [95%CI 42-55] vs. 57 mg [95%CI 52-61];p = .011)。
- 在24例主要使用AngioJet PowerPulse模式治疗的病例中,溶栓时间(27 h,95%CI 20-34,p < .001)和剂量(42 mg,95%CI 34-50,p = .009)的降低更为明显。
- PCDT组血红蛋白尿发生率增加(12/63 [19.0%] vs. 3/76 [3.9%];p = .006),但急性肾损伤无显著差异(3/63 [4.8%] vs. 1/76 [1.3%];p = .33);两组两年血管通畅率无显著差异(p = .73)。
临床怎么用
- 对于症状性急性髂股深静脉血栓,PCDT可作为减少溶栓剂量和缩短溶栓时间的选项,但需注意血红蛋白尿的发生。
- PCDT并未显著降低血栓后综合征发生率,临床决策需结合患者具体情况。
局限性
- 本研究为单中心回顾性队列研究,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Percutaneous thrombus removal is used for the treatment of iliofemoral deep vein thrombosis (DVT), but the efficacy of different treatment modalities has not yet been determined. The aim of this study was to compare the outcomes of patients treated with additional AngioJet pharmacomechanical thrombectomy (PCDT) vs. catheter directed lysis (CDT) alone. METHODS: A retrospective review of all patients who received thrombolysis for the treatment of symptomatic acute iliofemoral DVT between 2011 and 2017 was carried out. Outcome measures included the incidence of post-thrombotic syndrome (PTS), procedural outcomes (lytic exposure), the incidence of complications, and vessel patency. All patients were followed up for a minimum of one year. RESULTS: A total of 151 limbs were treated, 70 limbs with PCDT and 81 limbs with CDT alone. Demographic data and prevalence of risk factors were comparable. Incidence of PTS (Villalta score at one year) showed no significant difference (22.2% PCDT vs. 24.7% CDT alone, p = .74). Use of PCDT resulted in a non-statistically significant trend for fewer bleeds (n = 4/63 [6.3%] vs. 13/76 [17.1%]; relative risk 0.37, 95% confidence interval [CI] 0.13-1.08; p = .07), a statistically significant reduction in lysis duration (40 h [95% CI 34-46] vs. 53 h [95% CI 49-58]; p < .001) and a reduction in lytic dose (49 mg [95% CI 42-55] vs. 57 mg [95% CI 52-61]; p = .011) compared with CDT. This reduction was accentuated in 24 cases primarily treated with AngioJet PowerPulse mode (27 h, 95% CI 20-34 [p < .001] and 42 mg, 95% CI 34-50 [p = .009]). Incidences of complications were comparable between groups, with one death due to an intracranial haemorrhage following CDT. Although the incidence of haemoglobinuria was increased following PCDT (12/63 [19.0%] vs. 3/76 [3.9%]; p = .006), no significant difference in acute kidney injury was observed (3/63 [4.8%] vs. 1/76 [1.3%]; p = .33). No significant difference in vessel patency over two years was observed (p = .73). CONCLUSION: The use of PCDT for the treatment of iliofemoral DVT was observed to provide comparable patient outcomes, comparable vessel patency, an acceptable safety profile, and reduced overall lytic dose.
引用
- Pouncey AL, Gwozdz AM, Johnson OW, et al. AngioJet Pharmacomechanical Thrombectomy and Catheter Directed Thrombolysis vs. Catheter Directed Thrombolysis Alone for the Treatment of Iliofemoral Deep Vein Thrombosis: A Single Centre Retrospective Cohort Study. Eur J Vasc Endovasc Surg. 2020. PMID: 32665201. doi:10.1016/j.ejvs.2020.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。